Can a cancer drug ease long COVID? new trial tests LAU-7b
NCT ID NCT05999435
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an oral drug called LAU-7b (fenretinide) in 272 adults with moderate to severe Long COVID symptoms lasting at least 12 weeks. Participants took the drug or a placebo in cycles of 14 days on, 14 days off, for 12 weeks. The main goal was to see if LAU-7b improves physical health and daily function compared to placebo. Results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAU-7b (fenretinide)
What this could lead to
If it works, this could point toward a treatment that reduces physical symptoms and improves quality of life for people with Long COVID.
What could go wrong
This is a completed early-phase trial with modest size (272 people). Results are not yet published, so it's unclear if LAU-7b is better than placebo. Long COVID is complex and may not respond to a single drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIUSS du Saguenay-Lac-St-Jean - Hôpital Chicoutimi
Chicoutimi, Quebec, G7H 5H6, Canada
-
Centre Hospitalier de l'Université de Sherbrooke
Sherbrooke, Quebec, J1H 5N4, Canada
-
Diex Recherche Québec Inc.
Québec, Quebec, G1V 4T3, Canada
-
Institut de Recherches Cliniques de Montréal
Montreal, Quebec, H2W 1R7, Canada
-
Montreal General Hospital
Montreal, Quebec, H3G 1A4, Canada